PAX translocations remodel mitochondrial metabolism through altered leucine usage in rhabdomyosarcoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Aggressive alveolar rhabdomyosarcoma (ARMS) is driven by PAX3/7-FOXO1 fusion proteins. Targeting leucine bioavailability offers a promising strategy to impair tumor growth and improve survival in this childhood cancer.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Alveolar rhabdomyosarcoma (ARMS) with PAX3/7-FOXO1 fusions has poor prognosis.
- Effective therapies are urgently needed for this aggressive childhood cancer subtype.
Purpose Of The Study
- To investigate the mechanisms driving ARMS initiation and progression.
- To identify actionable therapeutic targets for PAX3/7-FOXO1-driven ARMS.
Main Methods
- Development of a muscle progenitor cell model for ARMS.
- Application of epigenomic approaches to analyze genome rewiring by PAX3/7 fusion proteins.
- Preclinical testing of identified molecular targets.
Main Results
- PAX3/7 fusion proteins rewire the genome, targeting oncogenes, FGF receptors, tRNA-modifying enzymes, and metabolism genes.
- Leucine utilization is critical for aggressive ARMS growth.
- Limiting leucine bioavailability impaired mitochondrial metabolism and oxidative phosphorylation, delaying tumor progression and improving survival in vivo.
Conclusions
- Leucine metabolism is a key vulnerability in PAX3/7-FOXO1-driven ARMS.
- Targeting leucine bioavailability presents a promising therapeutic strategy for ARMS.
- Identified targets offer new avenues for treating this aggressive childhood cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...